The U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded Moderna $176 million to produce an avian influenza H5N1 vaccine for humans applying mRNA technology as used for COVID vaccines. Moderna is currently testing their mRNA-1018 vaccine in volunteers with results available by December.